Clinical Trials Logo

Clinical Trial Summary

Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study.


Clinical Trial Description

This is a Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study. Subjects who meet all inclusion criteria and no exclusion criteria, will be randomized into the trial (Group A or B). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02453334
Study type Interventional
Source American Regent, Inc.
Contact
Status Completed
Phase Phase 3
Start date May 23, 2015
Completion date January 4, 2018